Thus, depending on the cancer cell context, URI1 can mediate ‘oncogene addiction’ as is the case in carcinomas with URI1 copy number increase [20] or ‘non-oncogene addiction’ as in CRCs, marking URI1 and the URI1C attractive targets to be exploited for cancer therapy. The gene discussed is URI1; the disease is carcinoma.